In conclusion, our findings demonstrate that rBCG exhibits superior tumor suppression effects in both in vitro and in vivo experimental conditions, and the enhanced therapeutic effects were closely linked to robust activation of innate and adaptive immune cells, particularly dendritic cells, CD4+ T cells, and CD8+ T cells, which orchestrated potent antitumor responses. This evidence concerns the gene CD4 and neoplasm.